Nyxoah Announces Partnership with ResMed in Germany

Nyxoah Announces Partnership with ResMed in Germany
Creates a continuum of care in the German obstructive sleep apnea market

Mont-Saint-Guibert, Belgium – September 28, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company has entered into a partnership with ResMed Germany to increase OSA awareness and therapy penetration in the German market.

Nyxoah and ResMed Germany will establish a continuum of care that will educate and guide OSA patients in the German market from diagnosis through treatment. Together, the companies will work to accelerate patient identification and better support patient set-up on the appropriate therapy. The companies will collaborate on:

  • OSA helplines and direct-to-consumer marketing initiatives
  • Sales and marketing efforts targeting ENTs and sleep physicians
  • Patient and clinician educational programs and symposiums

“We are thrilled to partner with ResMed Germany, as it strengthens further our patient-first approach to treating obstructive sleep apnea. OSA reduces quality of life and can result in other serious medical conditions, such as cardiovascular disease, and type 2 diabetes. Together, ResMed Germany and Nyxoah will heighten awareness of OSA and increase therapy penetration,” commented Olivier Taelman, Nyxoah’s Chief Executive Officer. “The OSA ecosystem created by this partnership will guide patients from diagnosis to the right treatment for them, whether that is a mandibular device, continuous positive airway pressure (CPAP), or hypoglossal nerve stimulation (HGNS).”

'It is our joint goal to enable more patients to receive effective, personalized therapy,” said Katrin Pucknat, President, ResMed Germany. “Over 95 percent of patients in Germany suffering from sleep apnea are not diagnosed or treated. In addition, there are patients who have problems with their therapy and just stop it without considering an alternative. The partnership with Nyxoah will enable us to broaden the education around therapy options and empower patients to benefit from improved health outcomes.”

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. 

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on March 22, 2023, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313


Attachment

  • ENGLISH_Nyxoah - RMD Parternship


Nyxoah Announces Partnership with ResMed in Germany

THỦ THUẬT HAY

Mách bạn mẹo sửa lỗi 0x81000036 khi sao lưu Windows 11

Nhiều người dùng Windows cho biết gặp thông báo lỗi với mã 0x81000036 khi khôi phục hệ thống về điểm khôi phục trước đó. Nếu bạn là một trong số đó thì dưới đây là cách giải quyết vấn đề.

Khắc phục và xử lý những lỗi thường gặp khi duyệt Web

Sử dụng trình duyệt web để làm việc hay cập nhật các thông tin thường nhật là việc làm thường ngày của mỗi người. Tuy nhiên đâu đó vẫn có khá nhiều người dùng thường xuyên gặp các lỗi phát sinh trong khi sử dụng. Bài

Windows Phone đã chết

Đó là tiêu đề từ trang công nghệ The Verge của Mỹ khi phân tích số liệu kinh doanh tệ hại của Windows Phone.

Hướng dẫn bật tính năng Lazy Loading - tăng tốc độ tải trang trên Chrome

Nội dung được tải trước sẽ hiển thị vừa với màn hình desktop hay thiết bị mobile của bạn, phần nội dung còn lại sẽ được tải thêm khi người dùng kéo xuống. Tính năng này không có gì mới, vì trước đây các nhà phát triển

Khắc phục tạm thời lỗi treo máy trên Windows 10 April 2018 Update

Ngay sau khi ra mắt, nhiều người dùng đã than phiền rằng phiên bản cập nhật Windows 10 April 2018 gặp lỗi, chẳng hạn như các lỗi về chuột máy tính, microphone và đặc biệt là một nghiêm trọng có liên quan đến trình

ĐÁNH GIÁ NHANH

So sánh camera iPhone 12 Pro vs Samsung Galaxy Note 20 Ultra

iPhone 12 Pro và Galaxy Note 20 Ultra là hai trong số những “camera phone” tốt nhất hiện nay. Vậy chiếc điện thoại nào sẽ tốt hơn trong việc chụp ảnh phong cảnh, chân dung, ảnh selfie và chế độ ban đêm?

Đánh giá HP Pavilion x360: Phù hợp với nhu cầu sử dụng laptop mỏng, nhẹ, đa năng

Là một sản phẩm thuộc dòng Pavilion, x360 được thừa hưởng khá nhiều điểm tương đồng với những người anh em của mình như: thiết kế bằng vỏ nhựa nguyên khối với màu vàng đồng đẹp mắt mang lại vẻ hiện đại cho sản phẩm.

Đánh giá camera Xperia XA1: Cảm biến Z5, chất lượng nâng cấp

Xperia XA1 sở hữu camera sau với độ phân giải lên đến 23 MP, khẩu độ mở ống kính là F/2.0, kích thước cảm biến 1/2.3''.